Altered structural network organization in cognitively normal individuals with amyloid pathology

Olga Voevodskaya a,∗, Joana B. Pereira a, Giovanni Volpe b, Olof Lindberg a, Erik Stomrud c,†, Danielle van Westen d,e, Eric Westman a,†, Oskar Hansson c,f,†

a Clinical Geriatrics, Department of Neurobiology, Care Sciences and Society, Karolinska Institute, Stockholm, Sweden
b Department of Physics, University of Gothenburg, Gothenburg, Sweden
c Clinical Geriatrics, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, Novum, Plan 5, Stockholm 141 86, Sweden
d Imaging and Function, Skåne University Health Care, Lund, Sweden
e Department of Clinical Sciences, Diagnostic radiology, Lund University, Lund, Sweden
f Clinical Memory Research Unit, Department of Clinical Sciences, Lund University, Malmö, Sweden

A R T I C L E   I N F O
Article history:
Received 4 July 2017
Received in revised form 10 November 2017
Accepted 30 November 2017
Available online 7 December 2017

Keywords:
Graph theory
Structural covariance networks
β-Amyloid
Global efficiency
Hubs
Alzheimer’s disease
Modularity

A B S T R A C T
Recent findings show that structural network topology is disrupted in Alzheimer’s disease (AD), with changes occurring already at the prodromal disease stages. Amyloid accumulation, a hallmark of AD, begins several decades before symptom onset, and its effects on brain connectivity at the earliest disease stages are not fully known. We studied global and local network changes in a large cohort of cognitively healthy individuals (N = 299, Swedish BioFINDER study) with and without amyloid-β (Aβ) pathology (based on cerebrospinal fluid Aβ42/Aβ40 levels). Structural correlation matrices were constructed based on magnetic resonance imaging cortical thickness data. Despite the fact that no significant regional cortical atrophy was found in the Aβ-positive group, this group exhibited an altered global network organization, including decreased global efficiency and modularity. At the local level, Aβ-positive individuals displayed fewer and more disorganized modules as well as a loss of hubs. Our findings suggest that changes in network topology occur already at the presymptomatic (preclinical) stage of AD and may precede detectable cortical thinning.

© 2017 Elsevier Inc. All rights reserved.

1. Introduction

In Alzheimer’s disease (AD), the loss of gray matter follows a characteristic pattern over time, spreading from medial temporal regions to temporoparietal association cortices, then to the neocortical areas (Thompson et al., 2003). A number of recent studies have proposed that cognitive decline in AD is a consequence of disruptions in the structural and functional connections between brain regions (Delbeuck et al., 2003). Studying brain structural covariance may expand our understanding of the organization of the brain at the different stages of disease progression.

AD begins 1 to 2 decades before any symptoms become apparent (Bateman et al., 2012). Asymptomatic individuals at risk for AD can be identified using validated pathophysiological biomarkers, such as cerebrospinal fluid markers of amyloid-β (Aβ) (Rosen et al., 2013). Cognitively healthy individuals with abnormal Aβ levels are considered to have preclinical AD (Sperling et al., 2011). Several studies have shown that asymptomatic individuals with evidence of cerebral amyloidosis have an increased risk of subsequent cognitive decline, including development of AD dementia (Insel et al., 2016; Jagust, 2016; Vos et al., 2013). Whether cognitively normal individuals with high amyloid burden display other abnormalities consistent with AD pathophysiology has been investigated across different magnetic resonance imaging (MRI) modalities. Most structural MRI (s-MRI) studies do not detect atrophy in normal individuals harboring brain amyloid. Some, however, have found a subtle degree of cortical thinning in asymptomatic amyloid-positive older controls (Dickerson et al., 2009). Further, high amyloid burden does not seem to influence white matter integrity measures in the absence of neurodegeneration in nondemented adults (Kantarcı et al., 2014). Functional MRI (fMRI) studies have found that increased brain amyloid load (Sheline et al., 2010) and lower cerebrospinal fluid (CSF) Aβ42 levels (Wang et al., 2013) are associated with decreases in functional connectivity in regions that belong to the default mode network (DMN) in cognitively healthy older individuals.
Gray matter networks are thought to reflect both actual connections via white matter tracts (as measured by diffusion tensor imaging) as well as intrinsic functional connectivity (as inferred from the blood-oxygen-level-dependent signal in fMRI) (Alexander-Bloch et al., 2013; Spreng and Turner, 2013). In neurodegeneration, cortical atrophy patterns give rise to covariance networks, which differ depending on the underlying pathology (Seeley et al., 2009). AD patients as well as asymptomatic adults at risk of developing AD (carriers of the apolipoprotein E [APOE] ε4 allele) have previously shown to display a different structural network organization compared to controls (Alexander et al., 2012; He et al., 2008). The extent of these network changes tends to reflect the magnitude of the underlying pathology, disease severity, and duration (Stam, 2014).

A widely used framework for investigating structural covariance networks is graph analysis. A graph theoretical approach allows assessing brain connectivity and network organization by representing the brain as a set of nodes connected by edges. When assessed network topology in preclinical AD (Tijms et al., 2016), our study includes a substantially larger number of cognitively normal Aβ+ participants, directly compares Aβ-positive and Aβ-negative groups and uses the CSF Aβ42/40 ratio as a biomarker of amyloid pathology. This ratio has recently shown to be more sensitive to Aβ deposition in prodromal AD than Aβ42, providing a better discrimination from other neurodegenerative disorders such as dementia with Lewy bodies and Parkinson’s disease dementia (Janelidze et al., 2016). In addition, in our study, we applied a methodology that overcomes the bias introduced by the varying number of edges when comparing groups (network densities are kept fixed so that the number of connections across groups is equal) and assessed network parameters that have not been previously evaluated in preclinical AD such as the modularity, transitivity, betweenness centrality, and community structure.

2. Materials and methods

2.1. Participants

All participants gave written consent to participate in the study. Ethical approval was given by the Ethical Committee of Lund University, Lund, Sweden.

The study population stemmed from the prospective and longitudinal Swedish BioFinder study (more information available at www.biofinder.se). The cohort consisted of cognitively normal elderly participants who were eligible for inclusion if they (1) were aged ≥60 years; (2) scored ≥28–30 points on the Mini-Mental State Examination at the screening visit; (3) did not suffer from any subjective cognitive impairment; and (4) were fluent in Swedish. Exclusion criteria included presence of significant neurologic disease (e.g., stroke, Parkinson’s disease, and multiple sclerosis), severe psychiatric disease (e.g., severe depression or psychotic syndromes), dementia, or MCI. These subjects underwent a thorough clinical assessment, including a comprehensive neuropsychological evaluation in the executive, visuospatial, language, and memory domains. A medical doctor made a global assessment of whether the individual was cognitively healthy based on the test results in relation to education and age. All subjects had a Clinical Dementia Rating scale score of 0.

For the present study, only participants with CSF analysis and a high-quality MRI scan were selected. This resulted in 233 healthy controls with normal CSF Aβ42/Aβ40 (CSF Aβ–) levels and 66 healthy controls with abnormal CSF Aβ42/Aβ40 levels. CSF Aβ42/Aβ40 ratio <0.1 was considered abnormal (Janelidze et al., 2016).

2.2. CSF collection and analysis

The procedure and analysis of the CSF followed the Alzheimer’s Association Flow Chart for CSF biomarkers. Lumbar CSF samples were collected at the 3 centers and analyzed in accordance with a standard protocol (Blennow et al., 2010). The CSF levels of Aβ42 and Aβ40 were determined using enzyme-linked immunosorbent assay (EUROIMMUN AG, Lübeck, Germany) (Janelidze et al., 2016).

2.3. MRI acquisition

MRI acquisition was performed on a 3T Siemens TrioTim scanner. The MRI protocol included a high-resolution coronal 3D T1-weighted magnetization-prepared rapid gradient-echo volume
دریافت فوری
متن کامل مقاله
امکان دانلود نسخه تمام متن مقالات انگلیسی
امکان دانلود نسخه‌ی ترجمه‌ی شده مقالات
پذیرش سفارش ترجمه‌ی تخصصی
امکان جستجو در آرشیو جامعی از صدها موضوع و هزاران مقاله
امکان دانلود رایگان ۲ صفحه اول هر مقاله
امکان پرداخت اینترنتی با کلیه‌ی کارت های عضو شتاب
دانلود فوری مقاله پس از پرداخت آنلاین
پشتیبانی کامل خرید با بهره مندی از سیستم هوشمند رهگیری سفارشات